Ornithine Cycle Disruption Drives Realgar-Induced CNS Toxicity

Study Background and Research Question

Realgar, an arsenic-containing mineral widely used in traditional Chinese medicine (TCM), has a long history of clinical application, particularly in multi-component formulations for neurological and inflammatory conditions. Despite its therapeutic heritage, realgar's chronic toxicity—especially central nervous system (CNS) effects—has raised increasing concern. Clinical observations of arsenic poisoning following prolonged or excessive realgar use include neurological, hepatic, and systemic manifestations. The molecular mechanisms underpinning these neurotoxic effects, particularly the interplay between hepatic metabolism and CNS function, remain incompletely understood.

The reference study (Ye et al., 2025) set out to illuminate this mechanistic gap. Specifically, it asked: How does realgar-induced disruption of hepatic metabolism—centered on ornithine transcarbamylase (OTC) and the ornithine cycle—mediate downstream effects on astrocyte energy metabolism and CNS toxicity?

Key Innovation from the Reference Study

The study's principal innovation lies in mechanistically linking hepatic OTC inhibition and ornithine accumulation to astrocyte dysfunction via the transcription factor ZBTB7A. By integrating conditional animal models, targeted cellular interventions, and multi-omics analyses, the authors demonstrate that realgar-derived arsenic not only accumulates in the brain but also impairs the hepatic ornithine cycle. This results in elevated systemic and CNS ornithine, which interacts with ZBTB7A in astrocytes to repress glycolytic gene expression, causing energy deficits and neuronal dysfunction. This cross-organ axis—from liver metabolic disruption to brain cellular energetics—offers a new paradigm for understanding arsenic neurotoxicity and highlights ornithine as a pivotal mediator in this process (Ye et al., 2025).

Methods and Experimental Design Insights

The authors employed a comprehensive suite of in vivo and in vitro models. Key design elements included:

• Conditional mouse models with hepatic OTC overexpression (Otc_{TBG OE}) and astrocyte-targeted Zbtb7a knockdown (Zbtb7a_{GfABC1D KD}).
• Exposure of these models to realgar, assessing both CNS and hepatic endpoints.
• Use of the C8-D1A astrocyte cell line, transfected with si-Zbtb7a, to dissect cell-autonomous metabolic responses to arsenic (iAs³⁺) and exogenous ornithine.
• Single-cell transcriptomics, global metabolomics, and classical neurobehavioral, molecular, and histopathological assessments.
• Molecular docking to probe ornithine–ZBTB7A interactions.

This multifaceted approach enabled the dissection of systemic (liver), cellular (astrocyte), and molecular (transcriptional/metabolic) layers of toxicity, with rigorous controls for specificity and causality.

Core Findings and Why They Matter

According to Ye et al. (2025), several key results emerged:

• Arsenic accumulation in the frontal lobe: Realgar-derived arsenic crosses the blood–brain barrier and concentrates in astrocytes.
• Suppression of astrocyte glycolysis: In astrocytes, arsenic triggers ZBTB7A-mediated repression of key glycolytic genes (Aldoa, Ldha, Pgam1), reducing lactate production and causing cellular energy deficits.
• Ornithine cycle disruption: Realgar exposure inhibits hepatic OTC, elevating ornithine in circulation and brain tissue. Elevated ornithine directly interacts with ZBTB7A, amplifying glycolytic repression and downstream neurotoxicity.
• Behavioral and neuropathological correlates: Mice exhibited impaired learning, memory, and exploratory behavior, alongside increased apoptosis and oxidative stress in the CNS.
• Pharmacological intervention: Chrysophanol, a natural anthraquinone, partially rescued both hepatic and CNS phenotypes by protecting OTC function and astrocyte glycolysis.

These findings establish a mechanistic chain: realgar-induced hepatic OTC inhibition leads to hyperornithinemia, which—through ZBTB7A—suppresses astrocyte glycolysis, ultimately precipitating CNS energy failure and neurotoxicity. This liver–brain metabolic axis refines our understanding of arsenic toxicity and may inform new diagnostics or therapeutic strategies for TCM-related adverse events.

Comparison with Existing Internal Articles

The present study extends and substantiates themes addressed in recent reviews and protocol articles on the role of L-Ornithine ((S)-2,5-diaminopentanoic acid) in metabolic research. For example, "L-Ornithine at the Crossroads of CNS–Liver Metabolism" outlined the importance of L-Ornithine as a urea cycle intermediate and its impact on ammonia detoxification pathways. The reference work by Ye et al. provides direct experimental evidence that connects these metabolic pathways to specific neurotoxic outcomes, highlighting the translational relevance of L-Ornithine for CNS–liver axis research. Similarly, the article "Ornithine Cycle Disruption and CNS Toxicity by Realgar" discusses the mechanistic linkage between hepatic ornithine dysregulation and astrocyte metabolism, which the present study now validates with in vivo and in vitro evidence.

Protocol-focused internal resources, such as "L-Ornithine in CNS–Liver Axis Research: Applied Protocols" and "L-Ornithine in Urea Cycle Research: Applied Workflows & Tips", offer practical guidance for modeling the ammonia detoxification pathway and optimizing metabolic enzyme assays. The experimental model and workflow parameters provided by Ye et al. can serve as a foundation for these protocol adaptations.

Protocol Parameters

• Animal model exposure: Realgar dosing in mice was calibrated to induce both hepatic and CNS toxicity; exposure duration and dose should reflect clinically relevant chronicity.
• OTC modulation: Hepatic overexpression or pharmacological protection of OTC can be used to dissect the specific contribution of urea cycle disruption.
• Astrocyte interventions: siRNA-mediated Zbtb7a knockdown in C8-D1A cells enables targeted study of ZBTB7A's role in glycolytic regulation.
• Ornithine supplementation: Exogenous L-Ornithine may be added to cell culture at concentrations matching in vivo hyperornithinemia, but careful titration is required to avoid off-target effects.
• Assay optimization: For metabolic enzyme assays or ammonia detoxification studies, select L-Ornithine solubility conditions compatible with aqueous or ethanolic buffers, as detailed in product specifications.

Limitations and Transferability

While the reference study establishes a clear mechanistic link between hepatic OTC inhibition, ornithine accumulation, and CNS dysfunction, several limitations remain. The animal models and exposure paradigms, while rigorous, may not fully recapitulate human dosing or chronic exposure scenarios typical of TCM misuse. Additionally, the molecular docking and in vitro experiments support but do not definitively prove ornithine–ZBTB7A interaction in vivo, leaving room for further validation by structural biology or direct protein binding assays. The role of additional metabolites, compensatory pathways, and the broader systemic response to arsenic exposure also warrants future investigation.

Nonetheless, the transferability of these findings to other models of metabolic neurotoxicity is high, particularly for researchers investigating urea cycle intermediates, astrocyte energy metabolism, or the liver–brain metabolic axis.

Research Support Resources

For researchers aiming to recapitulate or extend these findings, access to high-purity L-Ornithine ((S)-2,5-diaminopentanoic acid) is essential for modeling urea cycle disruptions and metabolic enzyme assays. L-Ornithine (SKU B8919) from APExBIO is supplied at ≥98% purity, with validated solubility data for aqueous and alcoholic solutions, and is suitable for rigorous biochemical and cell-based research workflows. Employing such reagents can support detailed studies of the ammonia detoxification pathway, astrocyte metabolism, and related neurotoxic mechanisms. For protocol strategies and troubleshooting, internal resources such as "L-Ornithine in CNS–Liver Axis Research" offer further methodological guidance.